Chemotherapy and Radiotherapy of Gastrointestinal Tumors

  • Hans Otto Klein

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 79)

Table of contents

  1. Front Matter
    Pages I-VII
  2. L. M. van Putten, E. A. Sluijter, T. Smink, J. H. Mulder
    Pages 10-18
  3. A. Gérard, M. Gignoux, A. Roussel, J. C. Goffin, A. Brugarolas, P. Zeitoun et al.
    Pages 19-27
  4. J. M. Gilbert, P. C. Cassell, H. Ellis, C. Wastell, K. Hellmann, M. G. Evans et al.
    Pages 48-58
  5. H. O. Klein, P. D. Wickramanayake, R. Voigtmann, Th. Löffler, R. Mohr, H. Oerkermann
    Pages 65-81
  6. W. Queißer, G. Schnitzler, J. Schaefer, H. Arnold, P. Drings, D. Fritze et al.
    Pages 82-92
  7. J. P. Obrecht, W. Weber, J. P. Cano, Ch. Crevoisier, P. Alberto, I. Forgo et al.
    Pages 101-107
  8. Back Matter
    Pages 109-114

About this book


Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10]. Of the few drugs which are active in the advanced disease, only 5-fluorouracil (5-FU) and razoxane «±1,2-bis(3,4-dioxopiperazin-1-yl)propane) are suitable for long-term adjuvant treatment [2, 9]. 5-FU has been widely and intensively studied as adjuvant chemotherapy in CRC [7], but there is no unanimity that it has even the marginal influence on survival that has been claimed [3, 10]. Razoxane has not previously been tested for adjuvant or maintenance treatment in CRC. It has however a number of biological activities which might be thought useful in the treatment of residual or minimal tumours [1] and which might therefore make it useful as an adjuvant. Thus it specifically prevents tumour dissemination and metastases in some tumours and normalizes the neovasculature which the tumours induce [6, 8, 11]. The drug is not cytotoxic in the usual sense, does not affect non-dividing cells, and only blocks cell division during a brief period of the cell cycle in late G and/or early mitosis [12]. It does so non-selectively and most cells capable of 2 division examined so far have been affected by the drug. Even affected cells however are not destroyed immediately, but may increase in size and become multinucleate [5].


Chemotherapy Radiotherapy Tumor Tumors therapy

Editors and affiliations

  • Hans Otto Klein
    • 1
  1. 1.Medizinische UniversitätsklinikKöln 41Germany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1981
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-81683-3
  • Online ISBN 978-3-642-81681-9
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology